Home/Filings/4/0001181431-10-010753
4//SEC Filing

Lwee Frederick 4

Accession 0001181431-10-010753

CIK 0001282393other

Filed

Feb 18, 7:00 PM ET

Accepted

Feb 19, 8:19 PM ET

Size

15.7 KB

Accession

0001181431-10-010753

Insider Transaction Report

Form 4
Period: 2010-02-16
Lwee Frederick
Principal Financial Officer
Transactions
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2010-02-1640,0000 total
    Exercise: $2.76Exp: 2019-09-02Common Stock (40,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2010-02-1690,0000 total
    Exercise: $1.80Exp: 2018-11-04Common Stock (90,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2010-02-1610,0000 total
    Exercise: $1.12Exp: 2019-01-22Common Stock (10,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2010-02-1644,0000 total
    Exercise: $1.18Exp: 2019-04-08Common Stock (44,000 underlying)
Footnotes (5)
  • [F1]Vine Acquisition Corp. (the "Purchaser"), initiated a tender offer pursuant to Purchaser's offer to purchase all of the outstanding shares of BioForm Medical, Inc. (the "Issuer") at a cash purchase price of $5.45 per share, without interest thereon, and less any applicable withholding taxes, subject to the terms described in the Offer to Purchase filed with the Securities and Exchange Commission on January 15, 2010 (the "Tender Offer") and the Agreement and Plan of Merger, dated as of December 31, 2009, by and among Merz GmbH & Co. KGaA, the Purchaser and the Issuer. On the date of grant, the shares underlying this option were to vest and become exercisable as to 1/4 of the shares on 09/02/2010 and quarterly vesting thereafter, with options being fully vested five years following the date of grant. (Continued in footnote 2).
  • [F2]The shares underlying this option, which were unvested at the closing of the Tender Offer, were canceled at the closing of the Tender Offer in exchange for the right to receive cash payment(s) representing the number of shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options, upon the date(s) the shares underlying this option would have otherwise become vested.
  • [F3]On the date of grant, the shares underlying this option were to vest and become exercisable as to 1/48 of the shares on 12/04/2008 and monthly thereof. 28,125 of the shares underlying these options, which were vested at the closing of the Tender Offer, were canceled at the closing of the Tender Offer in exchange for a cash payment of $102,656.25 representing the number of vested shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options. The remaining shares underlying these options, which were unvested at the closing of the Tender Offer, were canceled at the closing of the Tender Offer in exchange for the right to receive cash payment(s) representing the number of shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options, upon the date(s) the shares underlying this option would have otherwise become vested.
  • [F4]On the date of grant, the shares underlying this option were to vest and become exercisable as to 1/4 of the shares on 01/22/2010 and each anniversary thereof. 2,500 of the shares underlying these options, which were vested at the closing of the Tender Offer, were canceled at the closing of the Tender Offer in exchange for a cash payment of $10,825.00 representing the number of vested shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options. The remaining shares underlying these options, which were unvested at the closing of the Tender Offer, were canceled at the closing of the Tender Offer in exchange for the right to receive cash payment(s) representing the number of shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options, upon the date(s) the shares underlying this option would have otherwise become vested.
  • [F5]On the date of grant, the shares underlying this option were to vest and become exercisable as to 1/4 of the shares on 04/08/2010 and quarterly vesting thereafter, with options being fully vested four years following the date of grant. The shares underlying this option, which were unvested at the closing of the Tender Offer, were canceled at the closing of the Tender Offer in exchange for the right to receive cash payment(s) representing the number of shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options, upon the date(s) the shares underlying this option would have otherwise become vested.

Issuer

BIOFORM MEDICAL INC

CIK 0001282393

Entity typeother

Related Parties

1
  • filerCIK 0001463501

Filing Metadata

Form type
4
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 8:19 PM ET
Size
15.7 KB